New diabetes drug shows promise in early human tests
NCT ID NCT06685185
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested a new medicine called NNC0363-1063 in 117 healthy volunteers and people with type 1 diabetes. The goal was to check safety, how the body processes the drug, and its effect on blood sugar. The study had three parts, including single and multiple doses, and compared the drug to placebo and standard insulins.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NNC0363-1063
- What this could lead to
- If it works, this could point toward a new treatment option for type 1 diabetes that helps control blood sugar.
- What could go wrong
- This is a very early Phase 1 trial, so the drug may not prove safe or effective. Only 117 people are enrolled, and results may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Profil Institut für Stoffwechselforschung GmbH
Neuss, 41460, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a stress hormone be behind the hidden danger of low blood sugar?
- Can a peptide tame type 1 diabetes?
- Can a tiny implant track glucose, ketones, and lactate in diabetes?
- Wearable sensor could unmask hidden blood sugar chaos in stomach paralysis
- A smarter insulin that aims for the liver could curb dangerous nighttime dips
- Smart insulin pump may boost brain and body health in older adults with diabetes